AbolerIS Pharma
Nantes
About AbolerIS Pharma
AbolerIS Pharma has a novel and distinct therapeutic approach that induces immune tolerance and preserves useful immune responses in inflammatory, autoimmune, and degenerative diseases, allowing researchers to concentrate on the development of novel drugs in areas of unmet medical need.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $32.1M
- Funding stage: Early Stage Venture
- Last round: Series A (Sep 2023)
- Website: aboleris-pharma.com
Industries & Categories
Biotechnology
Social Profiles
Canonical: https://fsome.com/organization/aboleris-pharma-72335 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.